{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:09:02Z","timestamp":1789502942220,"version":"build-2803163510"},"reference-count":79,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2025,1,22]]},"DOI":"10.1080\/14656566.2025.2450360","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T09:22:17Z","timestamp":1735982537000},"page":"203-208","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["An update on emerging pharmacological treatments for meibomian gland dysfunction"],"prefix":"10.1080","volume":"26","author":[{"given":"Giulia","family":"Coco","sequence":"first","affiliation":[{"name":"University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-0289","authenticated-orcid":false,"given":"Giuseppe","family":"Giannaccare","sequence":"additional","affiliation":[{"name":"University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997d"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997c"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2003.09.019"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006324-199701000-00014"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997b"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997f"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307415"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1755441"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00262-8"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6703101"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000244875.92879.1a"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2019.03.004"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318225415a"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4445"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997e"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6997g"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.10.005"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.833778"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2015.04.005"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36590"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2019.07.008"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030529"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000258"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2020.12.006"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2020.08.004"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2021.11.08"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S48955"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000366"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.2326"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2005.19.4.258"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04322-1"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2022.0186"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.0302"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(85)90150-X"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2022.08.010"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/cxo.13035"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/17469899.2022.2147928"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002243"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000003046"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05363-1"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15764"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256533"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1089\/pho.2014.3819"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.8838"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04834-1"},{"key":"e_1_3_4_48_1","volume-title":"RESTASIS (cyclosporine ophthalmic emulsion) 0.05% for topical ophthalmic use. Package insert","author":"Allergan","year":"2017","unstructured":"Allergan. RESTASIS (cyclosporine ophthalmic emulsion) 0.05% for topical ophthalmic use. Package insert. Dublin: Allergan; 2017."},{"key":"e_1_3_4_49_1","unstructured":"VEVYE\u00ae Prescribing Information. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217469s000lbl.pdf"},{"key":"e_1_3_4_50_1","volume-title":"Cequa (cyclosporine ophthalmic solution) 0.09%, for topical ophthalmic use","author":"Sun Pharmaceutical Industries, Inc","year":"2019","unstructured":"Sun Pharmaceutical Industries, Inc. Cequa (cyclosporine ophthalmic solution) 0.09%, for topical ophthalmic use. Package insert. Mumbai: Sun Pharmaceutical Industries, Inc.; 2019."},{"key":"e_1_3_4_51_1","volume-title":"Xiidra (lifitegrast ophthalmic solution), for topical ophthalmic use. Package insert","author":"Novartis Pharmaceuticals Corporation","year":"2020","unstructured":"Novartis Pharmaceuticals Corporation. Xiidra (lifitegrast ophthalmic solution), for topical ophthalmic use. Package insert. Cambridge: Novartis Pharmaceuticals Corporation; 2020."},{"key":"e_1_3_4_52_1","volume-title":"Tyrvaya nasal spray. Package insert","author":"Oyster Point Pharma, Inc","year":"2021","unstructured":"Oyster Point Pharma, Inc. Tyrvaya nasal spray. Package insert. Princeton: Oyster Point Pharma, Inc.; 2021."},{"key":"e_1_3_4_53_1","volume-title":"EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, for topical ophthalmic use. package insert","author":"Kala Pharmaceuticals, Inc","year":"2020","unstructured":"Kala Pharmaceuticals, Inc. EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, for topical ophthalmic use. package insert. Watertown: Kala Pharmaceuticals, Inc.; 2020."},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S279051"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000176611.88579.0a"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31823cc098"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.08.015"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2018.11.002"},{"issue":"11","key":"e_1_3_4_59_1","first-page":"2434","article-title":"Parasympathetic innervation of the meibomian glands in rats","volume":"42","author":"LeDoux MS","year":"2001","unstructured":"LeDoux MS, Zhou Q, Murphy RB, et al. Parasympathetic innervation of the meibomian glands in rats. Invest Ophthalmol Vis Sci. 2001;42(11):2434\u20132441.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23553"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.03.005"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45475-7"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2269090"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2023.10.001"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0048"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2023.100704"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0042"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00669-1"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1159\/000542149"},{"key":"e_1_3_4_70_1","first-page":"692","article-title":"Keratolytic and keratostatic activity of selenium disulfide and its disease modifying role in meibomian gland disease","volume":"62","author":"Epstein-Barash H","year":"2021","unstructured":"Epstein-Barash H, Rapaport H, Alster Y, et al. Keratolytic and keratostatic activity of selenium disulfide and its disease modifying role in meibomian gland disease. Investig Ophthalmol Vis Sci. 2021;62:692.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"8","key":"e_1_3_4_71_1","first-page":"693","article-title":"Lipogenic activity of selenium disulfide and its role in enhancing lipid production in meibomian glands","volume":"62","author":"Alster Y","year":"2021","unstructured":"Alster Y, Epstein-Barash H, Rapaport H, et al. Lipogenic activity of selenium disulfide and its role in enhancing lipid production in meibomian glands. Investig Ophthalmol Vis Sci. 2021;62(8):693.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2023.07.002"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2024.11.008"},{"key":"e_1_3_4_74_1","volume-title":"ClinicalTrials.gov [Internet]","year":"2024","unstructured":"A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED). ClinicalTrials.gov [Internet]. Bethesda (MD); 2024 Nov 05. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06329791"},{"key":"e_1_3_4_75_1","unstructured":"Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction. ClinicalTrials.gov [Internet]. Bethesda (MD); 2024 Nov 05. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04469998"},{"key":"e_1_3_4_76_1","unstructured":"Safety Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction. ClinicalTrials.gov [Internet]. Bethesda (MD); 2024 Nov 05. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04884243"},{"key":"e_1_3_4_77_1","unstructured":"Safety Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction. ClinicalTrials.gov [Internet]. Bethesda (MD); 2024 Nov 05. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05261386"},{"key":"e_1_3_4_78_1","unstructured":"Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction. ClinicalTrials.gov [Internet]. Bethesda (MD); 2024 Nov 05. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03888378"},{"key":"e_1_3_4_79_1","unstructured":"The Efficacy and Safety of Topical Vitamin D Drop on Meibomian Gland Function in Patients With Meibomian Gland Dysfunction. ClinicalTrials.gov [Internet]. Bethesda (MD); 2024 Nov 05. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05495958"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.003"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2025.2450360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T04:11:14Z","timestamp":1738383074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2025.2450360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,22]]}},"alternative-id":["10.1080\/14656566.2025.2450360"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2025.2450360","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}